Skip to content
Home/Companies/Biotech/ArsenalBio
ArsenalBio

ArsenalBio

Biotech·United States·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns ArsenalBio?

ArsenalBio is an American Biotech company, currently owned by Hitachi Ventures since 2022.

Hand-verified · updated 2026-07-03

Open JSON · CC-BY
Hitachi Ventures
Investor
Hitachi Ventures
Hitachi Ventures Fund II · 2021 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive
Websitearsenalbio.com

More from Hitachi Ventures Fund II

Other portfolio companies in the same fund.

Ascend Elements
Active
EnergyUS· 2022
BeZero Carbon
BeZero Carbon
Active
ClimateTechUK· 2022
Makersite
Makersite
Active
SaaSGermany· 2022
Proscia
Proscia
Active
MedTechUS· 2022
Scipher Medicine
Scipher Medicine
Active
HealthTechUS· 2022
Weka
Active
SoftwareUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ArsenalBio?

ArsenalBio is currently owned by Hitachi Ventures, through Hitachi Ventures Fund II, since 2022.

When did Hitachi Ventures acquire ArsenalBio?

Hitachi Ventures acquired ArsenalBio in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue